Biomedical Research and Therapy

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients’ population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF.

After 21 days of transplantation, the results showed that the stem cell treated groups ameliorated better than the placebo group. MSC treated groups showed reduced AST and ALT levels, down-regulated expression of extracellular matrix (ECM) genes, and improved liver histopathology. Both sources of MSCs (bone marrow and adipose tissue) were effective in the mouse model of liver fibrosis.

The OR of placenta previa was 4.08 (95% CI= 1.44, 11.58) by maternal age, 4.08 (95% CI =1.44, 11.58) by preterm labor, and 6.64 (95% CI =1.09, 40.45) by prior operations of the uterine cavity, compared to normal deliveries and after adjusting for other variables. Multiparity, prior spontaneous abortions, and prior cesarean sections were not statistically significant risk factors for placenta previa, when adjusted for other variables.

QFSLN treatment showed enhanced effect over QF in a dose-dependent manner with minimal side effects in schizophrenic rats. In addition, immunohistochemical examinations of brain tissues confirmed the biochemical data.